Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT) Meeting Abstract


Authors: Feldman, D. R.; Hu, J. S.; Patil, S.; Reuter, V. E.; Srinivas, S.; Stadler, W. M.; Costello, B. A.; Milowsky, M. I.; Appleman, L. J.; Dorff, T. B.; Bromberg, M.; Joseph, G.; Funt, S. A.; Bajorin, D. F.; Bosl, G. J.; Quinn, D. I.; Motzer, R. J.
Abstract Title: Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT)
Meeting Title: 55th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 37
Issue: 15 Suppl.
Meeting Dates: 2019 May 31-Jun 4
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2019-05-20
Start Page: 279s
Language: English
ACCESSION: WOS:000487345805385
DOI: 10.1200/JCO.2019.37.15_suppl.4563
PROVIDER: wos
Notes: Meeting Abstract: 4563 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Sujata Patil
    511 Patil
  2. Dean Bajorin
    663 Bajorin
  3. Robert Motzer
    1251 Motzer
  4. Darren Richard Feldman
    348 Feldman
  5. Victor Reuter
    1234 Reuter
  6. George Bosl
    431 Bosl
  7. Samuel Aaron Funt
    143 Funt
  8. Gabriella Joseph
    5 Joseph